Evidence map›Paper›PMID 42835192›Full record

ArticleFrontiers in oncology2026

Comparative profiling of osimertinib and fourth-generation EGFR inhibitors on EGFR-mutant proteins and cell lines.

Janneke J T M Melis, Kirsten J W Kevenaar, Jacob Ytsma, Daphne J F Kluitmans, Janneke M van den End, Jeffrey J Kooijman, Jonne L K van Eck, Esmee van den Bossche, Jeroen A D M de Roos, Yusuke Kawase and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Janneke J T M MelisOncolines B.V., Oss, Netherlands.
Kirsten J W KevenaarOncolines B.V., Oss, Netherlands.
Jacob YtsmaOncolines B.V., Oss, Netherlands.
Daphne J F KluitmansOncolines B.V., Oss, Netherlands.
Janneke M van den EndOncolines B.V., Oss, Netherlands.
Jeffrey J KooijmanOncolines B.V., Oss, Netherlands.
Jonne L K van EckOncolines B.V., Oss, Netherlands.
Esmee van den BosscheOncolines B.V., Oss, Netherlands.
Jeroen A D M de RoosOncolines B.V., Oss, Netherlands.
Yusuke KawaseCarna Biosciences, Inc., Kobe, Japan.
Nicole Willemsen-SeegersOncolines B.V., Oss, Netherlands.
Yvonne GrobbenOncolines B.V., Oss, Netherlands.
Guido J R ZamanOncolines B.V., Oss, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Osimertinib is a third-generation, irreversible EGFR inhibitor that targets common activating EGFR mutations (ex19del and L858R) and the resistance EGFR mutation T790M. Clinical resistance to osimertinib frequently arises through the EGFR C797S mutation, which has driven the development of fourth-generation EGFR inhibitors. Methods: We performed side-by-side biochemical and cellular profiling of osimertinib and three fourth-generation EGFR inhibitors: BLU-945, JBJ-09-063 and silevertinib. Kinase assays were performed both at Results: Biochemical assays revealed distinct profiles among the fourth-generation EGFR inhibitors across different EGFR variants under Conclusion: This comparative analysis highlights the substantial differences in the activity landscapes of fourth-generation EGFR inhibitors. The gathered insights can provide direction for the optimal deployment of the inhibitors in distinct clinical contexts.

Indexed as

drug resistanceEGFRkinase inhibitornon-small cell lung cancerosimertinibsurface plasmon resonance

Identifiers

PMID42835192
PMCPMC13634975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.